+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Osteoporosis Drugs Market By Route of Administration, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5094292
  • Report
  • May 2020
  • Region: Global
  • 173 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan PLC
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • MORE
The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth of 4.4% CAGR during the forecast period. Osteoporosis is defined as a medical condition that is characterized by low bone density and quality in humans. Bones are brittle in this medical state, which renders them more vulnerable and, in effect, more susceptible to fractures. The condition is caused by the overproduction of a hormone called parathyroid.

The condition may lead to severe fractures, which may have harmful effects on the health of the patient. Nevertheless, the condition requires treatment, including the use of osteoporosis medications. Many of the drugs on the market include selective estrogen inhibitor modulator (SERM) bisphosphonates, parathyroid hormone treatment, calcitonin, and RANK ligand inhibitors. These drugs are administered through different routes in the body, like orally or intravenously.

International Osteoporosis Foundation reports that about 200 million people worldwide suffer from osteoporosis disorder. Currently, it is believed that about 200 million people globally suffer from this illness. About 30% of the postmenopausal people have osteoporosis in the US and Europe. According to the National Institute of Health, about 53 million people in the US are either suffering from osteoporosis or at elevated risk due to low bone density. The rising consumer base for osteoporosis disorders means steady demand development over the projected period.

Bisphosphonates are a type of drug used to reduce deterioration of the bone structure and to treat osteoporosis and related diseases. These are the most widely used medications used for the treatment of osteoporosis. They are called bisphosphonates because they have two groups of PO(OH) phosphonates. They are sometimes called diphosphonates (bis-or di-+phosphonates). Data shows that they reduce the likelihood of fracture in postmenopausal women with osteoporosis.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company.

Strategies deployed in Osteoporosis Drugs Market

2019-Apr: Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) approved EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.

2018-May: Amgen got the U.S. Food and Drug Administration (FDA) approval for the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

2017-Oct: Novartis signed an agreement with Daewoong Pharmaceutical. Under this agreement, the latter company has acquired marketing and commercial rights for an osteoporosis drug from Sandoz, Novartis’ generic division. By acquiring these rights, Daewoong strengthened its product lineup and secure a steady cash-flow.

2016-Sep: Amgen extended its collaboration with Dr. Reddy’s Laboratories Ltd. Following the expansion, Dr. Reddy was aimed to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.

2016-Jun: Amgen came into partnership with Zuellig Pharma following which the latter company helps the former company in driving growth of products and therapies in multiple markets across Asia. Zuellig was aimed to support Amgen with a range of services including Commercialization, Regulatory Services and Distribution. The partnership includes the commercialization of Amgen’s oncology therapeutics Neupogen, Neulastim, Vectibix, and XGEVA, and Amgen’s osteoporosis medicine Prolia, in nine Asian markets.

Scope of the Study

Market Segmentation:

By Route of Administration
  • Oral
  • Injectable and
  • Other Route of Administration
By Drug Class
  • Bisphosphonates
  • Rank Ligand Inhibitors
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Selective Estrogen Inhibitors Modulator (SERM) and
  • Other Drug Classes
By Geography

North America
  • US
  • Canada
  • Mexico
  • Rest of North America
Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Allergan PLC
  • Eli Lilly and Company
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan PLC
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Osteoporosis Drugs Market, by Route of Administration
1.4.2 Global Osteoporosis Drugs Market, by Drug Class
1.4.3 Global Osteoporosis Drugs Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Osteoporosis Drugs Market by Route of Administration
3.1 Global Oral Market by Region
3.2 Global Injectable Market by Region
3.3 Global Other Route of Administration Market by Region

Chapter 4. Global Osteoporosis Drugs Market by Drug Class
4.1 Global Bisphosphonates Market by Region
4.2 Global Rank Ligand Inhibitors Market by Region
4.3 Global Parathyroid Hormone Therapy Market by Region
4.4 Global Calcitonin Market by Region
4.5 Global Selective Estrogen Inhibitors Modulator (SERM) Market by Region
4.6 Global Other Drug Class Market by Region

Chapter 5. Global Osteoporosis Drugs Market by Region
5.1 North America Osteoporosis Drugs Market
5.1.1 North America Osteoporosis Drugs Market by Route of Administration
5.1.1.1 North America Oral Market by Country
5.1.1.2 North America Injectable Market by Country
5.1.1.3 North America Other Route of Administration Market by Country
5.1.2 North America Osteoporosis Drugs Market by Drug Class
5.1.2.1 North America Bisphosphonates Market by Country
5.1.2.2 North America Rank Ligand Inhibitors Market by Country
5.1.2.3 North America Parathyroid Hormone Therapy Market by Country
5.1.2.4 North America Calcitonin Market by Country
5.1.2.5 North America Other Drug Class Market by Country
5.1.3 North America Osteoporosis Drugs Market by Country
5.1.3.1 US Osteoporosis Drugs Market
5.1.3.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.3.1.2 US Osteoporosis Drugs Market by Drug Class
5.1.3.2 Canada Osteoporosis Drugs Market
5.1.3.2.1 Canada Osteoporosis Drugs Market by Route of Administration
5.1.3.2.2 Canada Osteoporosis Drugs Market by Drug Class
5.1.3.3 Mexico Osteoporosis Drugs Market
5.1.3.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
5.1.3.3.2 Mexico Osteoporosis Drugs Market by Drug Class
5.1.3.4 Rest of North America Osteoporosis Drugs Market
5.1.3.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
5.1.3.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class
5.2 Europe Osteoporosis Drugs Market
5.2.1 Europe Osteoporosis Drugs Market by Route of Administration
5.2.1.1 Europe Oral Market by Country
5.2.1.2 Europe Injectable Market by Country
5.2.1.3 Europe Other Route of Administration Market by Country
5.2.2 Europe Osteoporosis Drugs Market by Drug Class
5.2.2.1 Europe Bisphosphonates Market by Country
5.2.2.2 Europe Rank Ligand Inhibitors Market by Country
5.2.2.3 Europe Parathyroid Hormone Therapy Market by Country
5.2.2.4 Europe Calcitonin Market by Country
5.2.2.5 Europe Other Drug Class Market by Country
5.2.3 Europe Osteoporosis Drugs Market by Country
5.2.3.1 Germany Osteoporosis Drugs Market
5.2.3.1.1 Germany Osteoporosis Drugs Market by Route of Administration
5.2.3.1.2 Germany Osteoporosis Drugs Market by Drug Class
5.2.3.2 UK Osteoporosis Drugs Market
5.2.3.2.1 UK Osteoporosis Drugs Market by Route of Administration
5.2.3.2.2 UK Osteoporosis Drugs Market by Drug Class
5.2.3.3 France Osteoporosis Drugs Market
5.2.3.3.1 France Osteoporosis Drugs Market by Route of Administration
5.2.3.3.2 France Osteoporosis Drugs Market by Drug Class
5.2.3.4 Russia Osteoporosis Drugs Market
5.2.3.4.1 Russia Osteoporosis Drugs Market by Route of Administration
5.2.3.4.2 Russia Osteoporosis Drugs Market by Drug Class
5.2.3.5 Spain Osteoporosis Drugs Market
5.2.3.5.1 Spain Osteoporosis Drugs Market by Route of Administration
5.2.3.5.2 Spain Osteoporosis Drugs Market by Drug Class
5.2.3.6 Italy Osteoporosis Drugs Market
5.2.3.6.1 Italy Osteoporosis Drugs Market by Route of Administration
5.2.3.6.2 Italy Osteoporosis Drugs Market by Drug Class
5.2.3.7 Rest of Europe Osteoporosis Drugs Market
5.2.3.7.1 Rest of Europe Osteoporosis Drugs Market by Route of Administration
5.2.3.7.2 Rest of Europe Osteoporosis Drugs Market by Drug Class
5.3 Asia Pacific Osteoporosis Drugs Market
5.3.1 Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.3.1.1 Asia Pacific Oral Market by Country
5.3.1.2 Asia Pacific Injectable Market by Country
5.3.1.3 Asia Pacific Other Route of Administration Market by Country
5.3.2 Asia Pacific Osteoporosis Drugs Market by Drug Class
5.3.2.1 Asia Pacific Bisphosphonates Market by Country
5.3.2.2 Asia Pacific Rank Ligand Inhibitors Market by Country
5.3.2.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
5.3.2.4 Asia Pacific Calcitonin Market by Country
5.3.2.5 Asia Pacific Other Drug Class Market by Country
5.3.3 Asia Pacific Osteoporosis Drugs Market by Country
5.3.3.1 China Osteoporosis Drugs Market
5.3.3.1.1 China Osteoporosis Drugs Market by Route of Administration
5.3.3.1.2 China Osteoporosis Drugs Market by Drug Class
5.3.3.2 India Osteoporosis Drugs Market
5.3.3.2.1 India Osteoporosis Drugs Market by Route of Administration
5.3.3.2.2 India Osteoporosis Drugs Market by Drug Class
5.3.3.3 Japan Osteoporosis Drugs Market
5.3.3.3.1 Japan Osteoporosis Drugs Market by Route of Administration
5.3.3.3.2 Japan Osteoporosis Drugs Market by Drug Class
5.3.3.4 South Korea Osteoporosis Drugs Market
5.3.3.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
5.3.3.4.2 South Korea Osteoporosis Drugs Market by Drug Class
5.3.3.5 Singapore Osteoporosis Drugs Market
5.3.3.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
5.3.3.5.2 Singapore Osteoporosis Drugs Market by Drug Class
5.3.3.6 Malaysia Osteoporosis Drugs Market
5.3.3.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
5.3.3.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
5.3.3.7 Rest of Asia Pacific Osteoporosis Drugs Market
5.3.3.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.3.3.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
5.4 LAMEA Osteoporosis Drugs Market
5.4.1 LAMEA Osteoporosis Drugs Market by Route of Administration
5.4.1.1 LAMEA Oral Market by Country
5.4.1.2 LAMEA Injectable Market by Country
5.4.1.3 LAMEA Other Route of Administration Market by Country
5.4.2 LAMEA Osteoporosis Drugs Market by Drug Class
5.4.2.1 LAMEA Bisphosphonates Market by Country
5.4.2.2 LAMEA Rank Ligand Inhibitors Market by Country
5.4.2.3 LAMEA Parathyroid Hormone Therapy Market by Country
5.4.2.4 LAMEA Calcitonin Market by Country
5.4.2.5 LAMEA Other Drug Class Market by Country
5.4.3 LAMEA Osteoporosis Drugs Market by Country
5.4.3.1 Brazil Osteoporosis Drugs Market
5.4.3.1.1 Brazil Osteoporosis Drugs Market by Route of Administration
5.4.3.1.2 Brazil Osteoporosis Drugs Market by Drug Class
5.4.3.2 Argentina Osteoporosis Drugs Market
5.4.3.2.1 Argentina Osteoporosis Drugs Market by Route of Administration
5.4.3.2.2 Argentina Osteoporosis Drugs Market by Drug Class
5.4.3.3 UAE Osteoporosis Drugs Market
5.4.3.3.1 UAE Osteoporosis Drugs Market by Route of Administration
5.4.3.3.2 UAE Osteoporosis Drugs Market by Drug Class
5.4.3.4 Saudi Arabia Osteoporosis Drugs Market
5.4.3.4.1 Saudi Arabia Osteoporosis Drugs Market by Route of Administration
5.4.3.4.2 Saudi Arabia Osteoporosis Drugs Market by Drug Class
5.4.3.5 South Africa Osteoporosis Drugs Market
5.4.3.5.1 South Africa Osteoporosis Drugs Market by Route of Administration
5.4.3.5.2 South Africa Osteoporosis Drugs Market by Drug Class
5.4.3.6 Nigeria Osteoporosis Drugs Market
5.4.3.6.1 Nigeria Osteoporosis Drugs Market by Route of Administration
5.4.3.6.2 Nigeria Osteoporosis Drugs Market by Drug Class
5.4.3.7 Rest of LAMEA Osteoporosis Drugs Market
5.4.3.7.1 Rest of LAMEA Osteoporosis Drugs Market by Route of Administration
5.4.3.7.2 Rest of LAMEA Osteoporosis Drugs Market by Drug Class

Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments
6.1.4.1 Partnerships, Collaborations, and Agreements
6.1.4.2 Approvals
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments
6.5.4.1 Partnerships, Collaborations, and Agreements
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
Note: Product cover images may vary from those shown
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Allergan PLC
  • Eli Lilly and Company
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll